Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Extension Study of SYR110322 in Type 2 Diabetes
2005-004672-20Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of alogliptin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Takeda. Primary endpoints: Long-term safety of SYR110322 and Durability of glycemic control. Started Apr 2006; status: completed.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-004672-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004672-20.